Former Akcea president makes the leap to CEO seat at Avidity Biosciences; Astellas invests $12.5M into two incubators
→ After it was announced last week, in a surprise twist, that Akcea president Sarah Boyce along with her two top exec colleagues, CEO Paula Soteropoulos and COO Jeffrey Goldberg were hitting the exit at the Ionis spinoff, Boyce has found a new home. Boyce has been tapped to the helm of Avidity Biosciences — a company pioneering antibody-oligonucleotide conjugates (AOCs) — as their new CEO, president and board member. Boyce will draw from experience from her previous stints at Ionis, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.